FR2470599A1
(fr)
*
|
1979-12-07 |
1981-06-12 |
Panoz Donald |
Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
|
US4344929A
(en)
*
|
1980-04-25 |
1982-08-17 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
JPS5770816A
(en)
*
|
1980-10-17 |
1982-05-01 |
Ono Pharmaceut Co Ltd |
Multilayered film preparation of prostagladin of prolonged action
|
FR2525474A1
(fr)
*
|
1982-04-26 |
1983-10-28 |
Roussel Uclaf |
Nouvelle forme pharmaceutique orale de clometacine
|
US4478596A
(en)
*
|
1982-11-26 |
1984-10-23 |
Michelson Paul E |
Delivery system for physiologically active agents
|
US4613330A
(en)
*
|
1982-11-26 |
1986-09-23 |
Michelson Paul E |
Delivery system for desired agents
|
NZ206600A
(en)
*
|
1983-05-11 |
1987-01-23 |
Alza Corp |
Osmotic drug delivery device
|
JPH075457B2
(ja)
*
|
1983-08-16 |
1995-01-25 |
ザ ウエルカム フアウンデ−シヨン リミテツド |
調節された方法による有効成分の放出を可能にする医薬組成物
|
US4670578A
(en)
*
|
1983-08-29 |
1987-06-02 |
Merck & Co., Inc. |
Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
|
EP0137364A3
(de)
*
|
1983-09-23 |
1986-10-22 |
Merck & Co. Inc. |
Suppositoriumsform eines osmotischen therapeutischen Systems
|
US4627850A
(en)
*
|
1983-11-02 |
1986-12-09 |
Alza Corporation |
Osmotic capsule
|
GB2150434B
(en)
*
|
1983-12-01 |
1987-11-04 |
Alza Corp |
Constant rate release systems
|
GB2150830B
(en)
*
|
1983-12-05 |
1987-08-19 |
Alza Corp |
Drug dispenser
|
US4725427A
(en)
*
|
1984-03-13 |
1988-02-16 |
Albion International, Inc. |
Effervescent vitamin-mineral granule preparation
|
US4717566A
(en)
*
|
1984-03-19 |
1988-01-05 |
Alza Corporation |
Dosage system and method of using same
|
US4595583A
(en)
*
|
1984-03-19 |
1986-06-17 |
Alza Corporation |
Delivery system controlled administration of beneficial agent to ruminants
|
DE3586445T2
(de)
|
1984-06-26 |
1993-01-14 |
Merck & Co Inc |
Kondensierte benzo-laktam-verbindungen und deren pharmazeutische zusammensetzungen.
|
US4693895A
(en)
*
|
1984-10-26 |
1987-09-15 |
Alza Corporation |
Colon delivery system
|
US4624847A
(en)
*
|
1985-04-22 |
1986-11-25 |
Alza Corporation |
Drug delivery device for programmed delivery of beneficial drug
|
US4627971A
(en)
*
|
1985-04-22 |
1986-12-09 |
Alza Corporation |
Osmotic device with self-sealing passageway
|
US4675174A
(en)
*
|
1985-08-16 |
1987-06-23 |
Alza Corporation |
Veterinary dispenser delivering beneficial agent by gas power generated in situ
|
US4971790A
(en)
*
|
1986-02-07 |
1990-11-20 |
Alza Corporation |
Dosage form for lessening irritation of mocusa
|
US4723957A
(en)
*
|
1986-02-07 |
1988-02-09 |
Alza Corp. |
System for delivering drug with enhanced bioacceptability
|
US4662880A
(en)
*
|
1986-03-14 |
1987-05-05 |
Alza Corporation |
Pseudoephedrine, brompheniramine therapy
|
US4753802A
(en)
*
|
1986-03-19 |
1988-06-28 |
Alza Corporation |
Verapamil dosage form
|
US4847093A
(en)
*
|
1986-06-19 |
1989-07-11 |
Alza Corporation |
Dosage form with means for governing rate of gas formation
|
US5099063A
(en)
*
|
1986-11-05 |
1992-03-24 |
Merck & Co., Inc. |
Certain phosphinic acid derivatives having antibacterial activity
|
US4715994A
(en)
*
|
1986-11-05 |
1987-12-29 |
Merck & Co., Inc. |
Novel antibacterial agents and potentiators of carbapenem antibiotics
|
US5143908A
(en)
*
|
1986-11-05 |
1992-09-01 |
Merck & Co., Inc. |
Antibacterial agents and potentiators of carbapenem antibiotics
|
US4874388A
(en)
*
|
1987-06-25 |
1989-10-17 |
Alza Corporation |
Multi-layer delivery system
|
US4957494A
(en)
*
|
1987-06-25 |
1990-09-18 |
Alza Corporation |
Multi-layer delivery system
|
US5110597A
(en)
*
|
1987-06-25 |
1992-05-05 |
Alza Corporation |
Multi-unit delivery system
|
US5023088A
(en)
*
|
1987-06-25 |
1991-06-11 |
Alza Corporation |
Multi-unit delivery system
|
US5938654A
(en)
*
|
1987-06-25 |
1999-08-17 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
US5499979A
(en)
*
|
1987-06-25 |
1996-03-19 |
Alza Corporation |
Delivery system comprising kinetic forces
|
US5041644A
(en)
*
|
1987-07-06 |
1991-08-20 |
Merck & Co., Inc. |
Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
|
JPS6413097A
(en)
*
|
1987-07-06 |
1989-01-17 |
Mitsubishi Chem Ind |
Phosphonic acid derivative
|
EP0318066B1
(de)
|
1987-09-22 |
1992-07-29 |
Merck & Co. Inc. |
Aryl-substituierte Thiophen-3-ole, ihre Derivate und Analoge als Lipoxygenase-Inhibitoren
|
US5030732A
(en)
*
|
1988-03-03 |
1991-07-09 |
Merck & Co., Inc. |
Aminoethylphosphinic acid derivatives
|
CH675537A5
(de)
*
|
1988-03-25 |
1990-10-15 |
Ciba Geigy Ag |
|
US5211957A
(en)
*
|
1988-03-25 |
1993-05-18 |
Ciba-Geigy Corporation |
Solid rapidly disintegrating dosage form
|
US4962097A
(en)
*
|
1988-10-28 |
1990-10-09 |
Merck & Co., Inc. |
Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
|
US5145990A
(en)
*
|
1988-10-28 |
1992-09-08 |
Merck & Co., Inc. |
Phosphorous containing dhp enzyme inhibitors
|
US5147867A
(en)
*
|
1988-10-28 |
1992-09-15 |
Merck & Co., Inc. |
Phosphorus containing enzyme inhibitors
|
US4942039A
(en)
*
|
1989-05-09 |
1990-07-17 |
Miles Inc. |
Effervescent analgesic antacid composition having reduced sodium content
|
US5223264A
(en)
*
|
1989-10-02 |
1993-06-29 |
Cima Labs, Inc. |
Pediatric effervescent dosage form
|
US5089530A
(en)
|
1990-08-03 |
1992-02-18 |
Merck & Co., Inc. |
Novel fermentation product with antiparasitic activity
|
US5443459A
(en)
*
|
1991-01-30 |
1995-08-22 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
SG84487A1
(en)
|
1991-04-17 |
2001-11-20 |
Merck & Co Inc |
Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
|
US5198229A
(en)
*
|
1991-06-05 |
1993-03-30 |
Alza Corporation |
Self-retaining gastrointestinal delivery device
|
US5223265A
(en)
*
|
1992-01-10 |
1993-06-29 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery
|
US5639782A
(en)
*
|
1992-03-04 |
1997-06-17 |
Center For Innovative Technology |
Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
|
US5434151A
(en)
*
|
1992-08-24 |
1995-07-18 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
PT650485E
(pt)
|
1992-07-13 |
2001-03-30 |
Millennium Pharm Inc |
2,5-diaril-tetra-hidro-tiofenos -furanos e analogos para o tratamento de desordens inflamatorias e imunitarias
|
US5463083A
(en)
*
|
1992-07-13 |
1995-10-31 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5498255A
(en)
*
|
1993-08-17 |
1996-03-12 |
Alza Corporation |
Osmotic device for protracted pulsatile delivery of agent
|
US5403952A
(en)
*
|
1993-10-08 |
1995-04-04 |
Merck & Co., Inc. |
Substituted cyclic derivatives as novel antidegenerative agents
|
US5703093A
(en)
*
|
1995-05-31 |
1997-12-30 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5750565A
(en)
*
|
1995-05-25 |
1998-05-12 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5792776A
(en)
*
|
1994-06-27 |
1998-08-11 |
Cytomed, Inc., |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US6348571B1
(en)
|
1994-09-12 |
2002-02-19 |
Northwestern University |
Corticotropin release inhibiting factor and methods of using same
|
US5767113A
(en)
*
|
1995-05-10 |
1998-06-16 |
The Salk Institute For Biological Studies |
Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
|
CA2220451A1
(en)
*
|
1995-05-17 |
1996-11-21 |
Cedars-Sinai Medical Center |
Methods and compositions for improving digestion and absorption in the small intestine
|
US6861053B1
(en)
*
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
US6558708B1
(en)
|
1995-05-17 |
2003-05-06 |
Cedars-Sinai Medical Center |
Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
|
US7048906B2
(en)
*
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
US5817335A
(en)
*
|
1995-05-26 |
1998-10-06 |
Alza Corporation |
Osmotic device with high drug loading and delayed activation of drug delivery
|
US5800422A
(en)
*
|
1995-06-02 |
1998-09-01 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery and complete drug release
|
US5741815A
(en)
*
|
1995-06-02 |
1998-04-21 |
Lai; Ching-San |
Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
|
US5756540A
(en)
*
|
1995-06-02 |
1998-05-26 |
Mcw Research Foundation, Inc. |
Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
|
US6372713B1
(en)
*
|
1995-09-08 |
2002-04-16 |
The Board Of Trustees Of Northwestern University |
Anti-depressant effects of corticotropin release inhibiting factor
|
US5747532A
(en)
*
|
1995-11-21 |
1998-05-05 |
Medinox, Inc. |
Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
|
US6723531B2
(en)
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US5902605A
(en)
*
|
1996-04-18 |
1999-05-11 |
Alza Corporation |
Drug delivery device with minimal residual drug retention
|
US5785688A
(en)
*
|
1996-05-07 |
1998-07-28 |
Ceramatec, Inc. |
Fluid delivery apparatus and method
|
US5939460A
(en)
*
|
1996-07-08 |
1999-08-17 |
Idun Pharmaceuticals, Inc. |
Method of inhibiting NADPH oxidase
|
US5677318A
(en)
*
|
1996-07-11 |
1997-10-14 |
Merck Frosst Canada, Inc. |
Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
|
US5922761A
(en)
*
|
1996-09-06 |
1999-07-13 |
Medinox, Inc. |
Methods for in vivo reduction of iron levels and compositions useful therefor
|
JP2002511837A
(ja)
|
1996-09-10 |
2002-04-16 |
メデイノックス,インコーポレイテッド |
ポリジチオカルバメート含有マクロ分子と、治療及び診断用途へのその使用
|
US5858402A
(en)
*
|
1997-02-11 |
1999-01-12 |
Medinox, Inc. |
Methods for in vivo reduction of cyanide levels and compositions useful therefor
|
US5916910A
(en)
*
|
1997-06-04 |
1999-06-29 |
Medinox, Inc. |
Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
|
US5985592A
(en)
*
|
1997-06-05 |
1999-11-16 |
Dalhousie University |
Uses for pentoxifylline or functional derivatives/metabolites thereof
|
US6294350B1
(en)
|
1997-06-05 |
2001-09-25 |
Dalhousie University |
Methods for treating fibroproliferative diseases
|
US5840721A
(en)
*
|
1997-07-09 |
1998-11-24 |
Ontogen Corporation |
Imidazole derivatives as MDR modulators
|
US6797691B1
(en)
*
|
1997-07-23 |
2004-09-28 |
Northwestern University |
Methods and compositions for inhibiting angiogenesis
|
US7105496B2
(en)
*
|
1998-07-23 |
2006-09-12 |
Northwestern University |
Methods and compositions for inhibiting angiogenesis
|
US20030220234A1
(en)
*
|
1998-11-02 |
2003-11-27 |
Selvaraj Naicker |
Deuterated cyclosporine analogs and their use as immunodulating agents
|
CA2305703A1
(en)
|
1997-10-10 |
1999-04-22 |
David W. Christianson |
Compositions and methods for inhibiting arginase activity
|
CA2306096A1
(en)
|
1997-10-15 |
1999-04-22 |
Thomas Jefferson University |
Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
|
US6750201B1
(en)
*
|
1997-10-17 |
2004-06-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
|
US6984773B1
(en)
|
1998-01-09 |
2006-01-10 |
The Salk Institute For Biological Studies |
Transgenic mice expressing a human SXR receptor polypeptide
|
US6756491B2
(en)
|
1998-01-09 |
2004-06-29 |
The Salk Institute For Biological Studies |
Steroid-activated nuclear receptors and uses therefor
|
WO1999047549A1
(en)
*
|
1998-03-16 |
1999-09-23 |
Ontogen Corporation |
PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
|
US6287605B1
(en)
*
|
1998-04-17 |
2001-09-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treatment and prevention of HIV-1 infection
|
WO1999058640A2
(en)
|
1998-05-11 |
1999-11-18 |
Philadelphia Health And Education Corporation |
Mct-1, a human oncogene
|
US6333318B1
(en)
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US20030220258A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Robbert Benner |
Treatment of ischemic events
|
US20050203187A1
(en)
*
|
1998-06-01 |
2005-09-15 |
Verbiscar Anthony J. |
Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
|
US6093743A
(en)
|
1998-06-23 |
2000-07-25 |
Medinox Inc. |
Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
|
US6596770B2
(en)
|
2000-05-05 |
2003-07-22 |
Medinox, Inc. |
Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
|
US6265420B1
(en)
|
1998-06-23 |
2001-07-24 |
Medinox, Inc. |
Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
|
US20030064917A1
(en)
*
|
1998-07-23 |
2003-04-03 |
Crawford Susan E. |
Methods and compositions for inhibiting angiogenesis
|
WO2000009118A1
(en)
|
1998-08-13 |
2000-02-24 |
The Wistar Institute |
Methods for reducing atherosclerotic plaques
|
US6565854B2
(en)
|
1998-08-13 |
2003-05-20 |
Philadelphia Health And Education Corporation |
Antimicrobial histone H1 compositions, kits, and methods of use thereof
|
US6646113B1
(en)
*
|
1998-09-17 |
2003-11-11 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
|
US20020138856A1
(en)
*
|
1998-10-23 |
2002-09-26 |
Northwestern University |
Compositions and methods useful for treatment of depressive disorder based on an animal model
|
NZ512676A
(en)
|
1999-01-13 |
2003-01-31 |
Meditech Res Ltd |
A composition and method for the enhancement of the efficacy of drugs
|
US6395029B1
(en)
|
1999-01-19 |
2002-05-28 |
The Children's Hospital Of Philadelphia |
Sustained delivery of polyionic bioactive agents
|
US7282489B2
(en)
*
|
2000-01-19 |
2007-10-16 |
The Children's Hospital Of Philadelphia |
Compositions and methods for performing reverse gene therapy
|
WO2000041731A1
(en)
|
1999-01-19 |
2000-07-20 |
The Children's Hospital Of Philadelphia |
Reverse gene therapy
|
US7141417B1
(en)
*
|
1999-02-25 |
2006-11-28 |
Thomas Jefferson University |
Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
|
JP2002537383A
(ja)
|
1999-02-25 |
2002-11-05 |
メルク フロスト カナダ アンド カンパニー |
Pdeiv阻害化合物、組成物および治療方法
|
US6221855B1
(en)
|
1999-03-11 |
2001-04-24 |
Wake Forest University |
Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
US6025502A
(en)
*
|
1999-03-19 |
2000-02-15 |
The Trustees Of The University Of Pennsylvania |
Enantopselective synthesis of methyl phenidate
|
US6251927B1
(en)
|
1999-04-20 |
2001-06-26 |
Medinox, Inc. |
Methods for treatment of sickle cell anemia
|
EP1180114B1
(de)
|
1999-04-27 |
2011-09-21 |
The Trustees of The University of Pennsylvania |
Verwendung von Resistin spezifischen Antikörpern in der Behandlung von Diabetes
|
US6420545B1
(en)
*
|
1999-05-24 |
2002-07-16 |
The Trustees Of The University Of Pennsylvania |
CD4-independent HIV envelope proteins as vaccines and therapeutics
|
US7160694B2
(en)
|
1999-06-14 |
2007-01-09 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids encoding TANGO405 and functional fragments and uses thereof
|
US7033780B1
(en)
*
|
1999-06-14 |
2006-04-25 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
|
US6964854B1
(en)
*
|
1999-07-13 |
2005-11-15 |
Science & Technology Corporation |
Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
|
DE60041880D1
(de)
|
1999-10-08 |
2009-05-07 |
Taiji Biomedical Inc |
Verfahren zur verbesserung der chemotherapie
|
US20020147197A1
(en)
*
|
1999-10-08 |
2002-10-10 |
Newman Michael J. |
Methods and compositions for enhancing pharmaceutical treatments
|
ATE457317T1
(de)
|
1999-10-12 |
2010-02-15 |
Chemocentryx Inc |
Chemokine rezeptor
|
US6274627B1
(en)
|
1999-10-12 |
2001-08-14 |
Medinox, Inc. |
Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
JP3417370B2
(ja)
|
1999-12-09 |
2003-06-16 |
株式会社村田製作所 |
非可逆回路素子及び通信機装置
|
US6559128B1
(en)
*
|
2000-01-21 |
2003-05-06 |
Northwestern University |
Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
|
US20030212021A1
(en)
*
|
2001-01-25 |
2003-11-13 |
Frost Gregory I. |
Myeloid colony stimulating factor and uses thereof
|
US6464688B1
(en)
|
2000-02-15 |
2002-10-15 |
Microsolutions, Inc. |
Osmotic pump delivery system with flexible drug compartment
|
JP2001320205A
(ja)
|
2000-03-02 |
2001-11-16 |
Murata Mfg Co Ltd |
非可逆回路素子および通信装置
|
US7358330B2
(en)
*
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
DK1276491T3
(da)
*
|
2000-04-07 |
2007-02-05 |
Univ Pennsylvania |
Tamandarin- og didemnin-analoger og fremgangsmåder til fremstilling og anvendelse af dem
|
US6509315B1
(en)
|
2000-04-07 |
2003-01-21 |
The Trustees Of The University Of Pennsylvania |
Didemnin analogs and fragments and methods of making and using them
|
WO2001087870A1
(en)
*
|
2000-05-15 |
2001-11-22 |
Darwin Discovery Limited |
Hydroxamic acid derivatives
|
US6613801B2
(en)
|
2000-05-30 |
2003-09-02 |
Transtech Pharma, Inc. |
Method for the synthesis of compounds of formula I and their uses thereof
|
US20050026811A1
(en)
*
|
2003-05-20 |
2005-02-03 |
Mjalli Adnan M. M. |
Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
|
US6908741B1
(en)
|
2000-05-30 |
2005-06-21 |
Transtech Pharma, Inc. |
Methods to identify compounds that modulate RAGE
|
AU2001275043A1
(en)
|
2000-05-31 |
2001-12-11 |
Drugtech Corporation |
Mineral supplement
|
US6833357B2
(en)
*
|
2000-06-20 |
2004-12-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for modulating muscle cell and tissue contractility
|
US6429223B1
(en)
|
2000-06-23 |
2002-08-06 |
Medinox, Inc. |
Modified forms of pharmacologically active agents and uses therefor
|
US9066919B2
(en)
*
|
2000-07-14 |
2015-06-30 |
Alchemia Oncology Pty Limited |
Hyaluronan as a chemo-sensitizer in the treatment of cancer
|
AUPQ879500A0
(en)
*
|
2000-07-14 |
2000-08-10 |
Meditech Research Limited |
Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
|
KR20090036151A
(ko)
|
2000-07-19 |
2009-04-13 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 |
신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법
|
AU2001290629A1
(en)
*
|
2000-09-07 |
2002-03-22 |
Boehringer Ingelheim International G.M.B.H |
Heat shock response and virus replication
|
WO2002026240A2
(en)
*
|
2000-09-26 |
2002-04-04 |
Sidney Kimmel Cancer Center |
Inhibition of antigen presentation with poorly catabolized polymers
|
US20040102367A1
(en)
*
|
2001-02-23 |
2004-05-27 |
Gage Fred H |
Gene expression system based on chimeric receptors
|
WO2002070667A2
(en)
*
|
2001-03-05 |
2002-09-12 |
Transtech Pharma, Inc. |
High level insect expression of rage proteins
|
WO2002069965A1
(en)
*
|
2001-03-05 |
2002-09-12 |
Transtech Pharma, Inc. |
Benzimidazole derivatives as therapeutic agents
|
JP2005500254A
(ja)
*
|
2001-03-05 |
2005-01-06 |
トランス テック ファーマ,インコーポレイテッド |
治療因子としてのカルボキサミド誘導体
|
US7208279B2
(en)
*
|
2001-03-14 |
2007-04-24 |
Caden Biosciences, Inc. |
Method for identifying inhibitors of G protein coupled receptor signaling
|
US7294472B2
(en)
*
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
US6727287B2
(en)
|
2001-04-16 |
2004-04-27 |
Pts International, Inc. |
Toluene sulfonamide-containing anti-tumor composition and method of use thereof
|
US6632217B2
(en)
*
|
2001-04-19 |
2003-10-14 |
Microsolutions, Inc. |
Implantable osmotic pump
|
CN1157388C
(zh)
*
|
2001-05-29 |
2004-07-14 |
北京大学 |
哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
|
RU2259825C9
(ru)
|
2001-06-18 |
2006-04-10 |
БиоДием Лимитед |
Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US6884619B2
(en)
|
2001-07-17 |
2005-04-26 |
Yale University |
Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
|
US20030082720A1
(en)
*
|
2001-07-17 |
2003-05-01 |
Lifton Richard P. |
Compositions methods and kits relating to treating and diagnosing hypertension
|
GB0119396D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Celltech R&D Ltd |
Hydroxamic acid derivatives
|
ATE468861T1
(de)
*
|
2001-08-16 |
2010-06-15 |
Univ Pennsylvania |
Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
|
US9056048B2
(en)
*
|
2001-08-16 |
2015-06-16 |
The Trustees Of The University Of Pennsylvania |
Synthesis and use of cationic steroids for anti-inflammatory drug therapy
|
CN1578677A
(zh)
*
|
2001-08-27 |
2005-02-09 |
美迪泰克研究有限公司 |
改良的治疗方案
|
US20030069071A1
(en)
*
|
2001-09-28 |
2003-04-10 |
Tim Britt |
Entertainment monitoring system and method
|
PL210795B1
(pl)
|
2001-10-19 |
2012-03-30 |
Isotechnika Inc |
Sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (E), sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (Z), sposób stereoselektywnej syntezy izomeru (E) ISATX247, sposób stereoselektywnej syntezy izomeru (Z) ISATX247 i sposób wytwarzania mieszaniny izomerów ISATX247
|
US6555563B1
(en)
|
2001-11-16 |
2003-04-29 |
Medinox, Inc. |
Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
|
US7442512B2
(en)
*
|
2001-11-30 |
2008-10-28 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
US7413866B2
(en)
*
|
2001-11-30 |
2008-08-19 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
US7871619B2
(en)
*
|
2001-11-30 |
2011-01-18 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
US7253007B2
(en)
*
|
2001-11-30 |
2007-08-07 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
JP2005518391A
(ja)
|
2001-12-21 |
2005-06-23 |
ノボ ノルディスク アクティーゼルスカブ |
Gk活性化剤としてのアミド誘導体
|
AR038136A1
(es)
|
2002-01-24 |
2004-12-29 |
Merck Frosst Canada Inc |
Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
|
TW200302748A
(en)
*
|
2002-02-01 |
2003-08-16 |
Pfizer Prod Inc |
Osmotic delivery system
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
US20030161882A1
(en)
*
|
2002-02-01 |
2003-08-28 |
Waterman Kenneth C. |
Osmotic delivery system
|
US7378111B2
(en)
*
|
2002-02-20 |
2008-05-27 |
The Trustees Of The University Of Pennsylvania |
Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
|
ATE529110T1
(de)
*
|
2002-03-05 |
2011-11-15 |
Transtech Pharma Inc |
Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
|
US7282591B2
(en)
|
2002-04-11 |
2007-10-16 |
Merck & Co., Inc. |
1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
|
US7622117B2
(en)
*
|
2002-04-17 |
2009-11-24 |
Dynamis Therapeutics, Inc. |
3-deoxyglucosone and skin
|
US7378438B2
(en)
*
|
2002-04-19 |
2008-05-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
|
EP1501511A4
(de)
*
|
2002-05-06 |
2006-06-07 |
Univ Washington |
Verfahren zur behandlung von glaukom und anderen erkrankungen, die durch nos-2 expression vermittelt werden, durch hemmung des egfr-wegs
|
US20080051428A1
(en)
*
|
2002-05-15 |
2008-02-28 |
Davis Paul J |
Pyrroloquinoline quinone drugs and methods of use thereof
|
AUPS234402A0
(en)
*
|
2002-05-15 |
2002-06-13 |
Auckland Uniservices Limited |
Anti-tumour polycyclic carboxamides
|
NZ566263A
(en)
*
|
2002-05-24 |
2009-09-25 |
Millennium Pharm Inc |
CCR9 inhibitors and methods of use thereof
|
AU2003236500B9
(en)
|
2002-06-12 |
2009-07-02 |
Chemocentryx, Inc. |
1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
|
US7589199B2
(en)
|
2002-06-12 |
2009-09-15 |
Chemocentryx, Inc. |
Substituted piperazines
|
US6727241B2
(en)
|
2002-06-12 |
2004-04-27 |
Chemocentryx |
Anti-inflammatory compositions and methods of use
|
US7842693B2
(en)
*
|
2002-06-12 |
2010-11-30 |
Chemocentryx, Inc. |
Substituted piperazines
|
US20050256130A1
(en)
*
|
2002-06-12 |
2005-11-17 |
Chemocentryx, Inc. |
Substituted piperazines
|
US6620813B1
(en)
|
2002-06-21 |
2003-09-16 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
US20040077691A1
(en)
*
|
2002-06-21 |
2004-04-22 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
BR0312023A
(pt)
|
2002-06-27 |
2005-03-22 |
Novo Nordisk As |
Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
|
NZ539211A
(en)
|
2002-10-04 |
2008-05-30 |
Prana Biotechnology Ltd |
Neurologically-active compounds
|
WO2004037206A2
(en)
*
|
2002-10-23 |
2004-05-06 |
University Of Hawaii |
Methods for diagnosing and treating pre-term labor
|
EP1562975A2
(de)
*
|
2002-10-25 |
2005-08-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Steroide welche gruppen zur nachahmung von superoxidase dismutase sowie stickoxid donorgruppen beinhalten und ihre verwendung in der darstellung von medikamenten
|
EP1558250A4
(de)
|
2002-10-30 |
2006-11-02 |
Merck & Co Inc |
Gamma-aminoamid-modulatoren der chemokin-rezeptor-aktivitüt
|
US20040138301A1
(en)
|
2002-11-08 |
2004-07-15 |
Hansen Birgit Sehested |
Chemical uncouplers for the treatment of obesity
|
US20050143449A1
(en)
*
|
2002-11-15 |
2005-06-30 |
The Salk Institute For Biological Studies |
Non-steroidal farnesoid X receptor modulators and methods for the use thereof
|
AU2003298661B2
(en)
|
2002-11-18 |
2007-05-10 |
Chemocentryx, Inc. |
Aryl sulfonamides
|
US7741519B2
(en)
|
2007-04-23 |
2010-06-22 |
Chemocentryx, Inc. |
Bis-aryl sulfonamides
|
US20070021466A1
(en)
*
|
2002-11-18 |
2007-01-25 |
Solomon Ungashe |
CCR2 inhibitors and methods of use thereof
|
US7227035B2
(en)
*
|
2002-11-18 |
2007-06-05 |
Chemocentryx |
Bis-aryl sulfonamides
|
US7420055B2
(en)
|
2002-11-18 |
2008-09-02 |
Chemocentryx, Inc. |
Aryl sulfonamides
|
WO2004047755A2
(en)
*
|
2002-11-22 |
2004-06-10 |
Japan Tobacco Inc. |
Fused bicyclic nitrogen-containing heterocycles
|
US20060166894A1
(en)
*
|
2002-11-29 |
2006-07-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Ace-inhibitors having antioxidant and no-donor activity
|
ATE404543T1
(de)
|
2002-12-20 |
2008-08-15 |
Sosei R & D Ltd |
Benzoxazocine und ihre verwendung als monoamin- wiederaufnahme inhibitoren
|
AU2003300293B8
(en)
*
|
2002-12-20 |
2010-01-14 |
Chemocentryx, Inc. |
Inhibitors of the binding of chemokines I-TAC or SDF-1 to the CCXCKR2 receptor
|
AU2004204751A1
(en)
*
|
2003-01-09 |
2004-07-29 |
The Trustees Of The University Of Pennsylvania |
Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
|
AU2003900927A0
(en)
*
|
2003-02-28 |
2003-03-13 |
Biodiem Ltd |
Growth promotion method
|
AU2004224418A1
(en)
*
|
2003-03-21 |
2004-10-07 |
Madeleine M. Joullie |
Tamandarin analogs and fragments thereof and methods of making and using
|
ATE467616T1
(de)
|
2003-04-11 |
2010-05-15 |
High Point Pharmaceuticals Llc |
Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
US20060105036A1
(en)
|
2003-05-12 |
2006-05-18 |
Stephen Peroutka |
Threo-dops controlled release formulation
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
WO2005013907A2
(en)
*
|
2003-08-07 |
2005-02-17 |
Japan Tobacco Inc. |
Pyrrolo[1,2-b]pyridazine derivatives
|
JP2007501813A
(ja)
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク アクティーゼルスカブ |
新生血管形成と関連した症状を治療および診断するためのインターロイキン−20
|
WO2005025513A2
(en)
*
|
2003-09-12 |
2005-03-24 |
The Regents Of The Univeristy Of California |
Guanidinium derivatives for improved cellular transport
|
WO2005033297A1
(en)
*
|
2003-09-19 |
2005-04-14 |
The Rockefeller University |
Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
|
RU2381233C2
(ru)
|
2003-09-30 |
2010-02-10 |
Ново Нордиск А/С |
Агонисты рецептора меланокортина
|
EP2633866A3
(de)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Kombinationstherapie
|
US20100247540A1
(en)
*
|
2003-10-30 |
2010-09-30 |
Chemocentryx, Inc. |
Methods and Compositions For Modulating Angiogenesis
|
WO2005058280A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
EP1694650A1
(de)
*
|
2003-12-15 |
2006-08-30 |
Laboratoire Theramex |
1-n-phenylamino-1h-imidazolderivate und pharmazeutische zusammensetzungen, die diese enthalten
|
WO2005066145A1
(en)
|
2004-01-06 |
2005-07-21 |
Novo Nordisk A/S |
Heteroaryl-ureas and their use as glucokinase activators
|
US7435831B2
(en)
*
|
2004-03-03 |
2008-10-14 |
Chemocentryx, Inc. |
Bicyclic and bridged nitrogen heterocycles
|
AU2005219438B2
(en)
*
|
2004-03-03 |
2011-02-17 |
Chemocentryx, Inc. |
Bicyclic and bridged nitrogen heterocycles
|
US20060003020A1
(en)
*
|
2004-03-11 |
2006-01-05 |
The Regents Of The University Of Michigan |
Anti-metastatic ability of mibefradil and gadolinium
|
AU2005223847A1
(en)
|
2004-03-19 |
2005-09-29 |
Yale University |
Detection, isolation and uses of renalase (Monoamine Oxidase C)
|
WO2005092333A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
JP2007530563A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
(s)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用
|
US7169807B2
(en)
*
|
2004-04-09 |
2007-01-30 |
Allergan, Inc. |
10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
|
BRPI0511748A
(pt)
*
|
2004-06-01 |
2008-01-02 |
Univ Virginia |
composição farmacêutica, métodos para tratar cáncer e uma doença ou distúrbio associado com angiogênese em um indivìduo em necessidade, para inibir a proliferação de células endoteliais vasculares e cancerosas, e para preparar sc-2-71 e análogos do mesmo, rótulo de fotoafinidade de sc-2-71, método para interromper a polimerização dos microtúbulos em uma célula, e para identificar um análogo, análogo, e, kit para administrar uma composiçaõ farmacêutica a um indivìduo
|
CA2568306A1
(en)
|
2004-06-14 |
2005-12-22 |
Zoser B. Salama |
Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
|
US7740861B2
(en)
*
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
US20060292213A1
(en)
*
|
2004-06-23 |
2006-12-28 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of PDE-III mediated diseases
|
US8507411B2
(en)
*
|
2004-06-24 |
2013-08-13 |
Wisconsin Alumni Research Foundation |
Neoglycorandomization and digitoxin analogs
|
CA2571409C
(en)
*
|
2004-06-24 |
2012-01-24 |
Wisconsin Alumni Research Foundation |
Neoglycorandomization and digitoxin analogs
|
ATE435853T1
(de)
*
|
2004-07-02 |
2009-07-15 |
Allergan Inc |
Prostaglandinanaloga
|
UA92154C2
(ru)
*
|
2004-08-03 |
2010-10-11 |
Транстек Фарма, Инк. |
Rage-слитые белки и способы их применения
|
US7906552B2
(en)
|
2004-08-10 |
2011-03-15 |
Allergan, Inc. |
Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US7101904B2
(en)
*
|
2004-08-10 |
2006-09-05 |
Allergan, Inc. |
Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US7183310B2
(en)
*
|
2004-08-10 |
2007-02-27 |
Allergan, Inc. |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
EP1784179A4
(de)
|
2004-08-24 |
2010-03-31 |
Merck Sharp & Dohme |
Kombinationstherapie zur behandlung von cyclooxygenase-2-vermittelten krankheiten oder zuständen bei patienten mit risiko auf thrombotische kardiovaskuläre ereignisse
|
AU2005284727A1
(en)
|
2004-09-17 |
2006-03-23 |
University Of Massachusetts |
Compositions and their uses for lysosomal enzyme deficiencies
|
CA2582324A1
(en)
*
|
2004-10-01 |
2006-04-13 |
Merck & Co., Inc. |
Compositions and methods for treating ophthalmic diseases
|
EP1647549A1
(de)
|
2004-10-14 |
2006-04-19 |
Laboratoire Theramex |
Indazole, Benzisoxazole und Benzisothiazole mit oestrogenen Eigenschaften
|
US7612082B2
(en)
*
|
2004-10-28 |
2009-11-03 |
Allergan, Inc. |
Prostaglandin EP4 antagonists
|
US7101906B2
(en)
*
|
2004-11-16 |
2006-09-05 |
Allergan, Inc. |
2,3,4-substituted cyclopentanones as therapeutic agents
|
US7183324B2
(en)
|
2004-11-23 |
2007-02-27 |
Allergan, Inc. |
2,3,4-substituted cyclopentanones as therapeutic agents
|
WO2006058923A1
(en)
|
2004-12-03 |
2006-06-08 |
Novo Nordisk A/S |
Heteroaromatic glucokinase activators
|
US7091231B2
(en)
*
|
2004-12-10 |
2006-08-15 |
Allergan, Inc. |
12-Aryl prostaglandin analogs
|
CN101098700A
(zh)
*
|
2005-01-06 |
2008-01-02 |
默克公司 |
治疗炎性疾病的药物组合疗法和药用组合物
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
EP2474532A1
(de)
|
2005-01-14 |
2012-07-11 |
ChemoCentryx, Inc. |
Heteroarylsulfonamide und CCR2
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
TWI386208B
(zh)
*
|
2005-04-18 |
2013-02-21 |
Allergan Inc |
治療性的經取代環戊酮
|
PT1871804E
(pt)
*
|
2005-04-21 |
2013-10-31 |
Chemocentryx Inc |
Anticorpos que ligam ccx-ckr2
|
CN101166527A
(zh)
|
2005-04-27 |
2008-04-23 |
艾尼纳制药公司 |
用于治疗肥胖症和糖尿病以及其相关病况和用于治疗可通过增加血液glp-1含量改善的病况的组合疗法
|
US8420628B2
(en)
*
|
2005-05-06 |
2013-04-16 |
Allergan, Inc. |
Substituted beta-lactams
|
EP1721615A1
(de)
|
2005-05-09 |
2006-11-15 |
Komipharm International Co., Ltd. |
Pharmazeutische Zusammensetzung enthaltend Natrium- oder Kaliumarsenit zur Behandlung von Urogenitalkrebs und seinen Metastasen
|
CA2609402C
(en)
|
2005-05-23 |
2014-10-21 |
Sdg, Inc. |
Lipid construct for delivery of insulin to a mammal
|
AU2006254840B2
(en)
|
2005-06-08 |
2012-08-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
CA2612508A1
(en)
*
|
2005-06-17 |
2006-12-28 |
Dynamis Therapeutics, Inc. |
Treatment of inflammatory conditions
|
US7777035B2
(en)
|
2005-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
WO2007002701A2
(en)
|
2005-06-27 |
2007-01-04 |
Amgen Inc. |
Anti-inflammatory aryl nitrile compounds
|
US8039507B2
(en)
*
|
2005-06-29 |
2011-10-18 |
Allergan, Inc. |
Therapeutic substituted gamma lactams
|
WO2007006814A1
(en)
|
2005-07-14 |
2007-01-18 |
Novo Nordisk A/S |
Urea glucokinase activators
|
CN103784960A
(zh)
*
|
2005-07-27 |
2014-05-14 |
阿尔卡米亚肿瘤学股份有限公司 |
使用乙酰透明质酸的治疗方案
|
EP1948638B1
(de)
|
2005-08-12 |
2011-08-03 |
Schering Corporation |
Verbindungen zur behandlung entzündlicher erkrankungen
|
EP1924606A4
(de)
|
2005-08-25 |
2010-01-13 |
Repair Technologies Inc |
Vorrichtungen, zusammensetzungen und verfahren zum schutz und zur reparatur von zellen und gewebe
|
EP2325169B1
(de)
|
2005-08-29 |
2015-10-07 |
University Of Virginia Patent Foundation |
Lisofylline-analogue und ihre pharamazeutische verwendungen
|
US8871764B2
(en)
|
2005-08-29 |
2014-10-28 |
University Of Virginia Patent Foundation |
Lisofylline analogs and methods for use
|
US20130131007A1
(en)
|
2005-09-07 |
2013-05-23 |
Bebaas, Inc. |
Vitamin b12 compositions
|
US20070178141A1
(en)
*
|
2005-09-07 |
2007-08-02 |
Bebaas, Inc. |
Vitamin B12 compositions
|
AU2006289651B2
(en)
|
2005-09-07 |
2012-07-26 |
Alchemia Oncology Pty Limited |
Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
|
CA2626394A1
(en)
*
|
2005-10-24 |
2007-05-03 |
University Of Massachusetts |
Yeast cell wall particle for delivering osteoprotegerin-encoding polynucleotide
|
NZ568694A
(en)
|
2005-11-09 |
2011-09-30 |
Zalicus Inc |
Method, compositions, and kits for the treatment of medical conditions
|
WO2007059108A2
(en)
|
2005-11-10 |
2007-05-24 |
Chemocentryx, Inc. |
Substituted quinolones and methods of use
|
US7585895B2
(en)
*
|
2005-12-06 |
2009-09-08 |
Allergan, Inc. |
Therapeutic substituted cyclopentanes
|
US7427685B2
(en)
|
2005-12-06 |
2008-09-23 |
Allergan, Inc. |
Therapeutic substituted cyclopentanes
|
WO2007076379A2
(en)
*
|
2005-12-20 |
2007-07-05 |
Gilead Colorado, Inc. |
4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
|
US7323477B2
(en)
*
|
2006-02-02 |
2008-01-29 |
Allergan, Inc. |
7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
|
WO2007098240A2
(en)
*
|
2006-02-21 |
2007-08-30 |
Astrum Therapeutics Pty. Ltd. |
Compositions to reduce blood glucose levels and treat diabetes
|
ES2622493T3
(es)
*
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
EP1864692A1
(de)
*
|
2006-06-07 |
2007-12-12 |
Biotempt B.V. |
Verwendung von peptiden zum Schutz von Strahlenschäden
|
CA2645867A1
(en)
|
2006-03-20 |
2007-09-27 |
Allergan, Inc. |
Substituted gamma lactams as prostaglandin ep2 agonists
|
US20070225246A1
(en)
*
|
2006-03-27 |
2007-09-27 |
Denu John M |
O-acetyl-ADP-ribose non-hydrolyzable analogs
|
DK1971862T3
(da)
|
2006-04-11 |
2011-02-14 |
Arena Pharm Inc |
Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EP2012789B1
(de)
|
2006-04-14 |
2013-09-25 |
Prana Biotechnology Limited |
Verfahren zur Behandlung von altersbedingter Makuladegeneration (AMD)
|
US7439372B2
(en)
|
2006-05-03 |
2008-10-21 |
Allergan, Inc. |
Therapeutic compounds
|
US20090016981A1
(en)
|
2006-05-03 |
2009-01-15 |
Allergan, Inc. |
Therapeutic compounds
|
US7476755B2
(en)
|
2006-05-04 |
2009-01-13 |
Allergan, Inc. |
Therapeutic compounds
|
WO2008020902A1
(en)
|
2006-05-09 |
2008-02-21 |
Merck & Co., Inc. |
Substituted spirocyclic cgrp receptor antagonists
|
US7547727B2
(en)
|
2006-05-22 |
2009-06-16 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
US7550448B2
(en)
*
|
2006-05-24 |
2009-06-23 |
Allergan, Inc. |
Therapeutic compounds
|
US7553860B2
(en)
*
|
2006-06-14 |
2009-06-30 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
ES2564782T3
(es)
|
2006-07-05 |
2016-03-29 |
Merial, Inc. |
Compuestos derivados de 1-aril-5-alquil pirazol, procedimientos de fabricación y procedimientos de utilización de los mismos
|
ES2447065T3
(es)
|
2006-07-10 |
2014-03-11 |
Allergan, Inc. |
Derivados de ciclopentano sustituidos como agentes terapeuticos
|
EP2046762B1
(de)
|
2006-07-14 |
2011-02-16 |
ChemoCentryx, Inc. |
Triazolylphenylbenzensulfonamide
|
US8519135B2
(en)
*
|
2006-07-14 |
2013-08-27 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2/CCR9
|
US7700627B2
(en)
*
|
2006-07-26 |
2010-04-20 |
Allergan, Inc. |
Therapeutic substituted lactams
|
CA2658523C
(en)
|
2006-07-31 |
2012-06-12 |
Activesite Pharmaceuticals, Inc. |
Inhibitors of plasma kallikrein
|
US7985767B2
(en)
*
|
2006-09-06 |
2011-07-26 |
Allergan, Inc. |
Therapeutic amides
|
WO2008030618A1
(en)
|
2006-09-07 |
2008-03-13 |
Amgen Inc. |
Benzo-fused compounds for use in treating metabolic disorders
|
US8232254B2
(en)
*
|
2006-10-06 |
2012-07-31 |
Wisconsin Alumni Research Foundation |
Colchicine neoglycosides and methods for their synthesis and use
|
US8022061B2
(en)
|
2006-10-10 |
2011-09-20 |
Amgen Inc. |
N-aryl pyrazole compounds, compositions, and methods for their use
|
EP1920781B1
(de)
|
2006-11-10 |
2015-03-04 |
Glycotope GmbH |
Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren
|
WO2008073752A2
(en)
|
2006-12-11 |
2008-06-19 |
Allergan, Inc. |
Cyclobutyl derivatives for the treatment of glaucoma
|
GB0624757D0
(en)
|
2006-12-12 |
2007-01-17 |
Sosei R & D Ltd |
Novel compounds
|
MX2009006672A
(es)
|
2006-12-19 |
2009-10-26 |
Univ Virginia |
Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
|
US20080153825A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
|
WO2008079728A2
(en)
|
2006-12-22 |
2008-07-03 |
Allergan, Inc. |
Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
|
US20080153880A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
|
US20080153874A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
US20080153832A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
|
US20080153808A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
|
US20080153881A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
|
US20080153927A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan, Inc. |
Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
|
US20120083508A1
(en)
|
2006-12-22 |
2012-04-05 |
Allergan, Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
EP2097689A1
(de)
*
|
2006-12-28 |
2009-09-09 |
LG Electronics Inc. |
Eisherstellungssystem und verfahren zur eisherstellung eines kühlschrankes
|
US8318778B2
(en)
|
2007-01-11 |
2012-11-27 |
Novo Nordisk A/S |
Urea glucokinase activators
|
US20100221336A1
(en)
*
|
2007-02-14 |
2010-09-02 |
Logical Therapeutics, Inc. |
Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
|
CA2679301C
(en)
|
2007-02-28 |
2015-08-11 |
University Of Virginia Patent Foundation |
Lisofylline analogs and methods for use in protecting pancreatic .beta.-cells, treating type 1 diabetes, and treating inflammatory and autoimmune diseases
|
US8563594B2
(en)
*
|
2007-05-08 |
2013-10-22 |
Allergan, Inc. |
S1P3 receptor inhibitors for treating pain
|
KR101292600B1
(ko)
|
2007-05-15 |
2013-08-05 |
아벤티스 애그리컬쳐 |
아릴로아졸-2-일 시아노에틸아미노 화합물, 이의 제조방법 및 이의 사용방법
|
PL2155712T3
(pl)
|
2007-05-22 |
2017-02-28 |
Chemocentryx, Inc. |
3-(imidazolilo)-pirazolo[3,4-b]pirydyny
|
WO2008156721A1
(en)
|
2007-06-20 |
2008-12-24 |
Merck & Co., Inc. |
Diphenyl substituted alkanes
|
US7776877B2
(en)
|
2007-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
|
DK2175859T3
(da)
|
2007-07-12 |
2012-06-18 |
Chemocentryx Inc |
Kondenserede heteroarylpyridyl- og phenylbenzen-sulfonamider som ccr2-modulatorer til behandling af inflammation
|
WO2009012425A2
(en)
*
|
2007-07-19 |
2009-01-22 |
Logigal Therapeutics, Inc. |
Compositions including leukotriene antagonists and nsaids and methods of using the same
|
CN101827828B
(zh)
|
2007-08-07 |
2013-02-27 |
普罗萨里克斯有限公司 |
作为5-羟色胺能调节剂的1,2,4-三唑衍生物
|
US8962015B2
(en)
|
2007-09-28 |
2015-02-24 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
US8846053B2
(en)
|
2008-09-26 |
2014-09-30 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
EP2205072B1
(de)
|
2007-10-15 |
2013-11-20 |
The Salk Institute for Biological Studies |
Verfahren zur behandlung von verschiedenen krankheiten und beschwerden, sowie hierfür geeignete verbindungen
|
US8455548B2
(en)
*
|
2007-10-18 |
2013-06-04 |
Allergan, Inc. |
Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
|
US20100216857A1
(en)
*
|
2007-10-18 |
2010-08-26 |
Luhrs Lauren M B |
Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
|
US20110160265A1
(en)
*
|
2007-10-18 |
2011-06-30 |
Luhrs Lauren M B |
Method of treating motor disorders with alpha-2b adrenergic receptor agonists
|
US8389485B2
(en)
*
|
2007-10-29 |
2013-03-05 |
University Of Massachusetts |
Encapsulated nanoparticles for nucleic acid delivery
|
US8063033B2
(en)
*
|
2008-01-18 |
2011-11-22 |
Allergan, Inc. |
Therapeutic beta-lactams
|
US7956051B2
(en)
*
|
2008-01-24 |
2011-06-07 |
Allergan, Inc. |
Therapeutic amides and related compounds
|
US8633310B2
(en)
*
|
2008-02-19 |
2014-01-21 |
Allergan, Inc. |
Therapeutic substituted lactams
|
US8202855B2
(en)
|
2008-03-04 |
2012-06-19 |
Allergan, Inc |
Substituted beta-lactams
|
US7964596B2
(en)
|
2008-03-07 |
2011-06-21 |
Allergan, Inc. |
Therapeutic compounds
|
US20090233921A1
(en)
*
|
2008-03-11 |
2009-09-17 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
US7960379B2
(en)
*
|
2008-03-14 |
2011-06-14 |
Allergan, Inc. |
Therapeutic compounds
|
EP2262497A2
(de)
*
|
2008-03-17 |
2010-12-22 |
Allergan, Inc. |
S1p3-rezeptor-inhibitoren zur behandlung von entzündungen
|
US7732443B2
(en)
*
|
2008-03-18 |
2010-06-08 |
Yariv Donde |
Therapeutic substituted cyclopentanes
|
US8198318B2
(en)
*
|
2008-03-18 |
2012-06-12 |
Allergen, Inc. |
Therapeutic amides
|
US7960378B2
(en)
*
|
2008-03-18 |
2011-06-14 |
Allergan, Inc. |
Therapeutic compounds
|
US7705001B2
(en)
*
|
2008-03-18 |
2010-04-27 |
Allergan, Inc |
Therapeutic substituted gamma lactams
|
US7956055B2
(en)
*
|
2008-03-25 |
2011-06-07 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
EP2108960A1
(de)
*
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
|
US20090264433A1
(en)
*
|
2008-04-21 |
2009-10-22 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Triazine Derivatives
|
WO2009131951A2
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising isoxazole derivatives
|
US20090270398A1
(en)
*
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Pyridazine Derivatives
|
EP2278879B1
(de)
*
|
2008-04-21 |
2016-06-15 |
PATH Drug Solutions |
Verbindungen, zusammensetzungen und verfahren umfassend oxadiazolderivate
|
DK2291368T3
(da)
*
|
2008-04-24 |
2013-03-18 |
Allergan Inc |
Substitueret gamma-lactam som terapeutisk middel
|
AU2009239381A1
(en)
|
2008-04-24 |
2009-10-29 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
US7964634B2
(en)
*
|
2008-04-24 |
2011-06-21 |
Allergan, Inc. |
Therapeutic compounds
|
US7737140B2
(en)
*
|
2008-04-24 |
2010-06-15 |
Allergan, Inc. |
Therapeutic compounds
|
US8263593B2
(en)
*
|
2008-04-24 |
2012-09-11 |
Allergan, Inc. |
Therapeutic compounds
|
US7981887B2
(en)
*
|
2008-05-09 |
2011-07-19 |
Allergan, Inc. |
Therapeutic compounds
|
BRPI0912193A2
(pt)
*
|
2008-05-09 |
2015-10-06 |
Allergan Inc |
compostos terapêuticos.
|
US8530471B2
(en)
*
|
2008-05-09 |
2013-09-10 |
Allergan, Inc. |
Therapeutic cyclopentane derivatives
|
KR20110017878A
(ko)
*
|
2008-05-09 |
2011-02-22 |
알러간, 인코포레이티드 |
치료학적인 치환된 티아졸리딘온, 옥사졸리딘온, 및 관련 화합물
|
US8093282B2
(en)
*
|
2008-05-09 |
2012-01-10 |
Allergan, Inc. |
Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives
|
JP2011520807A
(ja)
|
2008-05-09 |
2011-07-21 |
アラーガン インコーポレイテッド |
治療用置換ヒダントイン類および関連化合物
|
WO2009137412A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Allergan, Inc. |
Therapeutic compounds
|
EP2291353B1
(de)
*
|
2008-05-20 |
2013-09-04 |
Allergan, Inc. |
Therapeutische prostaglandinverbindungen als wirkstoffe gegen okuläre hypotonie
|
EP2285775B1
(de)
*
|
2008-05-20 |
2017-03-22 |
Allergan, Inc. |
Zur Behandlung von unter anderem erhöhtem Augeninnendruck oder Alopezie geeignete Lactame
|
US8541603B2
(en)
*
|
2008-05-27 |
2013-09-24 |
Allergan, Inc. |
Substituted cyclopentanes or cyclopentanones as therapeutic agents
|
JP2011523958A
(ja)
|
2008-06-12 |
2011-08-25 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Cgrp受容体アンタゴニストとしての分岐状3−及び6−置換キノリン
|
CN105152919A
(zh)
|
2008-07-28 |
2015-12-16 |
赛丹思科大学 |
用于治疗代谢疾病的化合物
|
US20100022574A1
(en)
*
|
2008-07-28 |
2010-01-28 |
EndogenX, Inc. |
Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
|
WO2010019796A1
(en)
|
2008-08-14 |
2010-02-18 |
Chemietek, Llc |
Heterocyclic amide derivatives as ep4 receptor antagonists
|
US20110237528A1
(en)
*
|
2008-09-19 |
2011-09-29 |
Institute For Oneworld Health |
Compositions and methods comprising imidazole and triazole derivatives
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
KR101825870B1
(ko)
|
2008-11-14 |
2018-02-05 |
메리얼 인코포레이티드 |
거울상 이성질체가 풍부한 아릴로아졸-2-일 시아노에틸아미노 구충 화합물
|
EP2186521A1
(de)
|
2008-11-14 |
2010-05-19 |
Mergemeier Steffen |
Zusammensetzungen zur Behandlung und Prävention von Krankheiten mit bakteriellen, viralen und fungiziden Pathogenen und Fragmenten davon mit Polyvinylpyrrolidon und/oder Polyvinylpolypyrrolidon als therapeutisch aktive Verbindung
|
KR101660068B1
(ko)
|
2008-11-19 |
2016-09-26 |
메리얼 인코포레이티드 |
기생충 감염 치료를 위한 1-아릴피라졸 단독 또는 포름아미딘과의 조합을 포함하는 조성물
|
EA020496B1
(ru)
|
2008-11-21 |
2014-11-28 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
|
CN102282154B
(zh)
|
2008-12-04 |
2015-07-01 |
梅瑞尔公司 |
二聚的阿佛菌素和米尔倍霉素衍生物
|
DK3078658T3
(da)
|
2008-12-22 |
2019-07-15 |
Chemocentryx Inc |
C5ar-antagonister
|
DK2389372T3
(en)
|
2009-01-23 |
2015-12-14 |
Rigel Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITION OF JAK pathway
|
JP2012518005A
(ja)
|
2009-02-13 |
2012-08-09 |
アラーガン インコーポレイテッド |
4‐(1‐(3‐(ヒドロキシメチル)‐2‐メチルフェニル)エチル)‐1h‐イミダゾール‐2(3h)‐チオン
|
US8785468B2
(en)
|
2009-02-13 |
2014-07-22 |
Amgen Inc. |
Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
|
DK3566703T3
(da)
|
2009-02-13 |
2021-07-05 |
Allergan Inc |
Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
|
PL2401269T3
(pl)
|
2009-02-24 |
2014-07-31 |
Merck Sharp & Dohme |
Pochodne indolu jako antagoniści receptora CRTH2
|
GB0904044D0
(en)
|
2009-03-09 |
2009-04-22 |
Sosei R & D Ltd |
The treatment of inflammatory disorders and pain
|
WO2010103038A1
(en)
|
2009-03-11 |
2010-09-16 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
US8511216B2
(en)
*
|
2009-03-30 |
2013-08-20 |
Kanzaki Kokyukoki Mfg. Co., Ltd. |
Hydraulic actuator unit
|
CA2757480A1
(en)
*
|
2009-04-02 |
2010-10-07 |
Allergan, Inc. |
Prostaglandin e receptor antagonists
|
US8343976B2
(en)
*
|
2009-04-20 |
2013-01-01 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising pyrazole derivatives
|
CA2760775C
(en)
|
2009-05-05 |
2019-03-05 |
Vapogenix, Inc. |
Novel formulations of volatile anesthetics and methods of use for reducing inflammation
|
CA2761624C
(en)
|
2009-05-19 |
2016-10-18 |
Neuroderm Ltd. |
Compositions for continuous administration of dopa decarboxylase inhibitors
|
AU2010273977A1
(en)
|
2009-07-17 |
2012-02-02 |
Allergan, Inc. |
Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
|
CA2768543C
(en)
*
|
2009-07-28 |
2017-06-20 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
CA2770894A1
(en)
|
2009-08-11 |
2011-02-17 |
Allergan, Inc. |
Isothiozoles for treating conditions of the eye
|
US20110045522A1
(en)
*
|
2009-08-20 |
2011-02-24 |
Danchen Gao |
Methods for diagnosing diabetes and determining effectiveness of treatments
|
CA2772354A1
(en)
|
2009-08-26 |
2011-03-10 |
Daniel W. Gil |
Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
|
WO2011028455A1
(en)
|
2009-09-02 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
WO2011034951A2
(en)
|
2009-09-15 |
2011-03-24 |
The Regents Of The University Of California |
Assisted enzyme replacement therapy
|
US8293925B2
(en)
|
2009-09-21 |
2012-10-23 |
Chemocentryx, Inc. |
Pyrrolidinone carboxamide derivatives
|
WO2011041198A1
(en)
|
2009-09-30 |
2011-04-07 |
Transtech Pharma, Inc. |
Substituted imidazole derivatives for treatment of alzheimers disease
|
WO2011066414A1
(en)
|
2009-11-25 |
2011-06-03 |
Cytometix, Inc. |
Arachidonic acid analogs and methods for analgesic treatment using same
|
JP5780681B2
(ja)
|
2009-12-04 |
2015-09-16 |
メリアル リミテッド |
殺有害生物性二有機硫黄化合物
|
NZ600845A
(en)
|
2009-12-17 |
2014-08-29 |
Merial Ltd |
Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
|
RU2549900C9
(ru)
|
2009-12-17 |
2016-09-20 |
Мериал Лимитед |
Противопаразитарные дигидроазоловые соединения и содержащие их композиции
|
CA2784799C
(en)
|
2009-12-30 |
2014-06-10 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain dipeptidyl peptidase inhibtors
|
AU2011210352A1
(en)
|
2010-01-26 |
2012-08-09 |
Radikal Therapeutics Inc. |
Compositions and methods for prevention and treatment of pulmonary hypertension
|
US9090584B2
(en)
*
|
2010-01-26 |
2015-07-28 |
Allergan, Inc. |
Therapeutic agents for treatment of ocular hypertension
|
US8299068B2
(en)
*
|
2010-01-29 |
2012-10-30 |
Allergan, Inc. |
Therapeutically active cyclopentanes
|
JP6045347B2
(ja)
|
2010-02-03 |
2016-12-14 |
ファーマ ツー ビー リミテッド |
ラサギリンの持続放出性製剤およびその使用
|
GB201002530D0
(en)
|
2010-02-15 |
2010-03-31 |
Univ Wolverhampton The |
Di-aspirin derivatives
|
WO2011103091A1
(en)
|
2010-02-18 |
2011-08-25 |
Transtech Pharma, Inc. |
Phenyl-heteroaryl derivatives and methods of use thereof
|
JP5814948B2
(ja)
|
2010-02-18 |
2015-11-17 |
ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー |
置換縮合イミダゾール誘導体、その医薬組成物、及び使用の方法
|
US8853212B2
(en)
|
2010-02-22 |
2014-10-07 |
Merck Sharp & Dohme Corp |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
|
AU2011238616B2
(en)
|
2010-03-30 |
2016-08-04 |
Verseon Corporation |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
UA108641C2
(uk)
|
2010-04-02 |
2015-05-25 |
|
Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
|
WO2011130716A2
(en)
|
2010-04-16 |
2011-10-20 |
Access Pharmaceuticals, Inc. |
A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
|
WO2011133596A1
(en)
|
2010-04-20 |
2011-10-27 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
|
EP2560654A1
(de)
|
2010-04-20 |
2013-02-27 |
Institute for OneWorld Health |
Verbindungen, zusammensetzungen und verfahren mit pyridazin-sulfonamid-derivaten
|
WO2011141909A2
(en)
|
2010-05-10 |
2011-11-17 |
Radikal Therapeutics Inc. |
Lipoic acid and nitroxide derivatives and uses thereof
|
EP2571876B1
(de)
|
2010-05-21 |
2016-09-07 |
Merck Sharp & Dohme Corp. |
Substituierte siebenteilige heterozyklische verbindungen als dipeptidyl-peptidase-iv-hemmer zur behandlung von diabetes
|
HUE036009T2
(hu)
|
2010-05-26 |
2018-06-28 |
Vtv Therapeutics Llc |
Metformin alkalmazása kombinációban egy glukokináz aktivátorral, és kompozíciók, amelyek metformint és egy glukokináz aktivátort tartalmaznak
|
ES2664872T3
(es)
|
2010-06-18 |
2018-04-23 |
Taiho Pharmaceutical Co., Ltd |
Moduladores PRPK-TPRKB y sus usos
|
DK2585064T3
(en)
|
2010-06-24 |
2017-07-24 |
Chemocentryx Inc |
C5aR antagonists
|
AU2011270872A1
(en)
|
2010-06-24 |
2013-01-31 |
Allergan, Inc. |
Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
|
US8492424B2
(en)
|
2010-07-01 |
2013-07-23 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
US8859606B2
(en)
|
2010-07-01 |
2014-10-14 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
EP2588630A4
(de)
|
2010-07-02 |
2013-12-25 |
Univ Virginia Patent Found |
Molekularer genetischer ansatz zur behandlung und diagnose von alkohol- und drogenabhängigkeit
|
US9714238B2
(en)
|
2010-07-02 |
2017-07-25 |
Allergan, Inc. |
Therapeutic agents for ocular hypertension
|
WO2012003145A2
(en)
|
2010-07-02 |
2012-01-05 |
Allergan, Inc. |
Therapeutic agents for ocular hypertension
|
BR112013001632B1
(pt)
|
2010-07-28 |
2021-05-25 |
Rigel Pharmaceuticals |
composto, composição farmacêutica, e, método de fabricar um composto
|
MX2013001234A
(es)
|
2010-08-05 |
2013-04-24 |
Conrig Pharma Aps |
Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
|
KR20190097323A
(ko)
|
2010-08-16 |
2019-08-20 |
알러간, 인코포레이티드 |
알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
|
AR082492A1
(es)
|
2010-08-20 |
2012-12-12 |
Allergan Inc |
N-alquil-2-(1-(5-sustituido-2-(3-oxo-3-(trifluorometilsulfonamido)propil)bencil)pirrolidin-2-il)oxazol-4-carboxamida y su uso para preparar un medicamento util para tratar enfermedades o afecciones mediadas por receptor dp, fp, ep, ep, tp y/o ep
|
WO2012032513A1
(en)
|
2010-09-07 |
2012-03-15 |
Bar-Ilan University |
Boranophosphate derivatives for the treatment of osteoarthritis
|
US20130209368A1
(en)
|
2010-09-09 |
2013-08-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd |
Near infrared fluorescent particles and uses thereof
|
GB201016880D0
(en)
|
2010-10-07 |
2010-11-17 |
Riotech Pharmaceuticals Ltd |
Phosphodiesterase inhibitors
|
MX353625B
(es)
|
2010-10-15 |
2018-01-22 |
Contera Pharma Aps |
Combinaciones de agonistas del receptor de serotonina para el tratamiento de trastornos de movimiento.
|
US20130315934A1
(en)
|
2010-10-28 |
2013-11-28 |
Yale University |
Methods and Compositions for Assessing and Treating Cancer
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
TWI487706B
(zh)
|
2010-11-12 |
2015-06-11 |
Merck Sharp & Dohme |
六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑
|
HUE037005T2
(hu)
|
2010-11-15 |
2018-08-28 |
Neuroderm Ltd |
L-dopának, dopa dekarboxiláz inhibitoroknak, katechol-O-metil transzferáz inhibitoroknak és ezekhez szolgáló kompozícióknak folyamatos bevezetése
|
MX2013005414A
(es)
|
2010-11-16 |
2013-08-29 |
Centre Nat Rech Scient |
Derivados de monensina novedosos para el tratamiento y prevencion de infecciones por protozoarios.
|
WO2012071525A2
(en)
|
2010-11-24 |
2012-05-31 |
Yale University |
Compositions and methods for diagnosing and treating diseases and disorders associated with d-dt
|
WO2012070040A1
(en)
|
2010-11-26 |
2012-05-31 |
Technion Research And Development Foundation Ltd |
Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
|
CA2819457A1
(en)
|
2010-12-03 |
2012-06-07 |
Allergan, Inc. |
Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
|
WO2012078633A2
(en)
|
2010-12-07 |
2012-06-14 |
Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene |
Methods of inhibiting metastasis from cancer
|
GB201020860D0
(en)
|
2010-12-09 |
2011-01-26 |
Univ Wolverhampton |
Disulfiram formulation and uses thereof
|
MX353720B
(es)
|
2010-12-15 |
2018-01-25 |
Contravir Pharmaceuticals Inc |
Moleculas analogas de ciclosporina modificadas en el aminoacido 1 y 3.
|
WO2012087777A1
(en)
|
2010-12-22 |
2012-06-28 |
Merck Sharp & Dohme Corp. |
Fused heterocyclic indane carboxamide cgrp receptor antagonists
|
WO2012093383A1
(en)
|
2011-01-04 |
2012-07-12 |
Radikal Therapeutics Inc. |
Compositions and methods for treatment of sepsis and related conditions
|
US9211263B2
(en)
|
2012-01-06 |
2015-12-15 |
Elcelyx Therapeutics, Inc. |
Compositions and methods of treating metabolic disorders
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
US11759441B2
(en)
|
2011-01-07 |
2023-09-19 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
US9572784B2
(en)
|
2011-01-07 |
2017-02-21 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
DK2661266T3
(da)
|
2011-01-07 |
2020-11-16 |
Anji Pharma Us Llc |
Kemosensoriske receptorligandbaserede terapier
|
US9480663B2
(en)
|
2011-01-07 |
2016-11-01 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
EP2683410A2
(de)
|
2011-03-08 |
2014-01-15 |
Access Pharmaceuticals, Inc. |
Gezielte nanocarrier-systeme zur freisetzung von wirkstoffen durch biologische membranen
|
KR101802011B1
(ko)
|
2011-03-10 |
2017-11-27 |
리겔 파마슈티칼스, 인크. |
원반성 루푸스에 사용하기 위한 2,4 치환 피리미딘디아민
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
MY161199A
(en)
|
2011-03-23 |
2017-04-14 |
Amgen Inc |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
CA2832422C
(en)
|
2011-04-06 |
2020-07-28 |
Mcw Research Foundation, Inc. |
Epoxyeicosatrienoic acid analogs and methods of making and using the same
|
JP6054368B2
(ja)
|
2011-04-08 |
2016-12-27 |
カルダン セラピューティクス リミテッドCaldan Therapeutics Limited |
代謝性疾患治療用o−フルオロ置換化合物またはその塩
|
EP2696897A2
(de)
|
2011-04-11 |
2014-02-19 |
Yeda Research and Development Co. Ltd. |
Albuminbindende sonden und wirkstoffkonjugate daraus
|
WO2012142308A1
(en)
|
2011-04-13 |
2012-10-18 |
Activesite Pharmaceuticals, Inc. |
Prodrugs of inhibitors of plasma kallikrein
|
US20140294957A1
(en)
|
2011-04-18 |
2014-10-02 |
Maxdelbruck-Centrum Fur Molekulare Medizin |
Niclosamide for the treatment of cancer metastasis
|
MX362218B
(es)
|
2011-05-04 |
2019-01-09 |
Balance Therapeutics Inc |
Derivados de pentilentetrazol.
|
EP2707020A4
(de)
|
2011-05-09 |
2015-01-14 |
Univ Virginia Patent Found |
Zusammensetzungen und verfahren zur behandlung von krebs
|
WO2012166533A1
(en)
|
2011-05-27 |
2012-12-06 |
Allergan, Inc. |
D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders
|
WO2012163365A1
(en)
|
2011-06-01 |
2012-12-06 |
Concit Pharma Aps |
Combinations of serotonin receptor agonists for treatment of movement disorders
|
EP2720691A1
(de)
|
2011-06-17 |
2014-04-23 |
Allergan, Inc. |
D-serin zur behandlung von störungen des sehapparats
|
WO2013003168A1
(en)
|
2011-06-27 |
2013-01-03 |
Merial Limited |
Novel insect-repellent coumarin derivatives, syntheses, and methods of use
|
EA201400058A1
(ru)
|
2011-06-27 |
2014-07-30 |
Мериал Лимитед |
Соединения и композиции на основе амидопиридиловых эфиров и их применение против паразитов
|
WO2013005216A1
(en)
|
2011-07-05 |
2013-01-10 |
Radikal Therapeutics Inc. |
Compositions and methods for treatment of renal ischemia-reperfusion injury
|
BR112014001951A2
(pt)
|
2011-07-25 |
2017-02-21 |
Allergan Inc |
derivados de n-(imidazolidin-2-ilideno)-heterociclopenta[b]piridina como moduladores dos receptores adrenérgicos alfa 2
|
US8609658B2
(en)
|
2011-07-27 |
2013-12-17 |
Allergan, Inc. |
N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
|
WO2013019169A1
(en)
|
2011-08-01 |
2013-02-07 |
Institute For Oneworld Health |
Phosphate prodrugs
|
EP3045173A3
(de)
|
2011-09-09 |
2016-09-14 |
The University of Virginia Patent Foundation |
Molekularer genetischer ansatz zur behandlung und diagnose von alkohol- und drogenabhängigkeit
|
WO2013036290A1
(en)
|
2011-09-09 |
2013-03-14 |
Yale University |
Compositions and methods for assessing and treating inflammatory diseases and disorders
|
AU2012312305B2
(en)
|
2011-09-22 |
2016-11-17 |
Merck Sharp & Dohme Corp. |
Acyclic cyanoethylpyrazoles as janus kinase inhibitors
|
WO2013052355A1
(en)
|
2011-10-03 |
2013-04-11 |
Merck Sharp & Dohme Corp. |
Azaindoles as janus kinase inhibitors
|
CN103957912B
(zh)
|
2011-11-03 |
2019-04-05 |
台湾微脂体股份有限公司 |
疏水性喜树碱衍生物的药物组合物
|
US10980798B2
(en)
|
2011-11-03 |
2021-04-20 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
US9173404B2
(en)
|
2011-11-17 |
2015-11-03 |
Merial, Inc. |
Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof
|
US9713605B2
(en)
|
2011-11-18 |
2017-07-25 |
Simpson Biotech Co., Ltd. |
Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death
|
AU2012340806B2
(en)
|
2011-11-21 |
2017-10-19 |
Allergan, Inc. |
Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
|
ES2648340T3
(es)
|
2011-12-01 |
2018-01-02 |
Chemocentryx, Inc. |
Benzoimidazoles y benzopirazoles substituidos como antagonistas de CCR(4)
|
PT2785692T
(pt)
|
2011-12-01 |
2018-01-04 |
Chemocentryx Inc |
Anilinas substituídas como antagonistas do ccr(4)
|
PT3351546T
(pt)
|
2011-12-02 |
2024-03-07 |
Boehringer Ingelheim Vetmedica Gmbh |
Formulações injectáveis de moxidectina com ação prolongada
|
WO2013085802A1
(en)
|
2011-12-06 |
2013-06-13 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
AU2012358983B2
(en)
|
2011-12-21 |
2017-09-14 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
JP6124187B2
(ja)
|
2011-12-21 |
2017-05-10 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
一般的な抗炎症反応を与える複数のプロスタグランジン受容体において作用する化合物
|
US9035071B2
(en)
|
2011-12-27 |
2015-05-19 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
AU2012362579B2
(en)
|
2011-12-27 |
2017-08-31 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
CN110693868A
(zh)
|
2012-01-06 |
2020-01-17 |
埃尔舍利克斯治疗公司 |
双胍组合物和治疗代谢性病症的方法
|
EA033067B1
(ru)
|
2012-01-06 |
2019-08-30 |
Элселикс Терапьютикс, Инк. |
Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
|
EP2814485A4
(de)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
Dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
|
US8916601B2
(en)
|
2012-02-29 |
2014-12-23 |
Chemocentryx, Inc. |
Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides
|
JP6231548B2
(ja)
|
2012-03-23 |
2017-11-15 |
マテオン セラピューティクス, インコーポレイテッド |
カテプシンの阻害のための組成物および方法
|
WO2013151982A1
(en)
|
2012-04-03 |
2013-10-10 |
Arena Pharmaceuticals, Inc. |
Methods and compounds useful in treating pruritus, and methods for identifying such compounds
|
KR20140145624A
(ko)
|
2012-04-16 |
2014-12-23 |
카네크 파마 인코포레이티드 |
Ptp-1b 억제제에 대한 전구체로서의 융합된 방향족 포스포네이트 유도체
|
WO2013156861A2
(en)
|
2012-04-17 |
2013-10-24 |
University College Dublin, National University Of Ireland, Dublin |
Methods and compounds for treating proliferative disorders and viral infections
|
WO2013156871A2
(en)
|
2012-04-17 |
2013-10-24 |
University College Dublin, National University Of Ireland, Dublin |
Thromboxane receptor antagonists
|
CA2870123C
(en)
|
2012-04-18 |
2021-02-23 |
Contera Pharma Aps |
Orally available pharmaceutical formulation suitable for improved management of movement disorders
|
WO2013169574A2
(en)
|
2012-05-09 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
Aliphatic spirolactam cgrp receptor antagonists
|
US9296750B2
(en)
|
2012-05-09 |
2016-03-29 |
Merck Sharp & Dohme Corp. |
Spirolactam CGRP receptor antagonists
|
EP2846801B1
(de)
|
2012-05-09 |
2017-04-05 |
Merck Sharp & Dohme Corp. |
Pyridin-cgrp-rezeptorantagonisten
|
WO2013173506A2
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
US20150368197A1
(en)
|
2012-06-21 |
2015-12-24 |
Radikal Therapeutics Ins. |
Compositions and methods for treatment of inflammatory diseases of the lung
|
US20140024621A1
(en)
|
2012-07-23 |
2014-01-23 |
Ms Therapeutics Limited |
Aminopyridine compounds and their uses
|
EP2874622A4
(de)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
Behandlung von diabetes mit dipeptidylpeptidase-iv-hemmern
|
US9555012B2
(en)
|
2012-08-09 |
2017-01-31 |
Dynamis Therapeutics, Inc. |
Methods for maintaining or improving health, well-being and/or a physiological function in a subject
|
WO2014036022A1
(en)
|
2012-08-29 |
2014-03-06 |
Amgen Inc. |
Quinazolinone compounds and derivatives thereof
|
JP2015528501A
(ja)
|
2012-09-12 |
2015-09-28 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
白斑の治療法
|
AU2013333765B2
(en)
|
2012-10-19 |
2017-12-07 |
Txp Pharma Gmbh |
Alpha- and gamma-MSH analogues
|
EP2920172B1
(de)
|
2012-11-16 |
2019-12-25 |
Merck Sharp & Dohme Corp. |
Purinhemmer von humaner phosphatidylinosit-3-kinase delta
|
CN104884453B
(zh)
|
2012-11-20 |
2018-06-22 |
梅里亚股份有限公司 |
驱蠕虫化合物和组合物和使用其的方法
|
US9328116B2
(en)
|
2012-12-07 |
2016-05-03 |
Chemocentryx, Inc. |
Diazole lactams
|
CA2894715C
(en)
|
2012-12-21 |
2021-06-15 |
Chemocentryx, Inc. |
Diazole amides
|
WO2014113814A1
(en)
|
2013-01-21 |
2014-07-24 |
Allergan, Inc. |
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
|
EP2948150A1
(de)
|
2013-01-25 |
2015-12-02 |
Rigel Pharmaceuticals, Inc. |
Verbindungen und verfahren zur behandlung von darmentzündungskrankheiten
|
WO2014134774A1
(en)
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
JP6373881B2
(ja)
|
2013-03-05 |
2018-08-15 |
ザルツマン・グループ・インコーポレイテッドSalzman Group, Inc. |
多機能酸化窒素誘導体のプロドラッグおよびその使用
|
WO2014141261A1
(en)
|
2013-03-13 |
2014-09-18 |
Neuroderm Ltd |
Method for treatment of parkinson's disease
|
UA116648C2
(uk)
|
2013-03-14 |
2018-04-25 |
Алкермес Фарма Айерленд Лімітед |
Фумарати як проліки та їх застосування при лікуванні різних захворювань
|
MX2015011567A
(es)
|
2013-03-15 |
2016-04-25 |
Verseon Corp |
Halogeno-pirazoles como inhibidores de trombina.
|
EP3421036B8
(de)
|
2013-03-15 |
2020-12-30 |
Verseon International Corporation |
Multisubstituierte aromatische verbindungen als serinproteaseinhibitoren
|
WO2014179263A1
(en)
|
2013-04-30 |
2014-11-06 |
Allergan, Inc. |
Therapeutic agents
|
US9000032B2
(en)
|
2013-05-31 |
2015-04-07 |
Allergan, Inc. |
Substituted cyclopentenes as therapeutic agents
|
WO2015003082A2
(en)
|
2013-07-02 |
2015-01-08 |
Cineole Corp., Llc |
Volatile organic compound formulations having antimicrobial activity
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
EP3035800B1
(de)
|
2013-08-22 |
2019-10-09 |
Merck Sharp & Dohme Corp. |
Verbindungen zur hemmung der wiederholungsaktivität eines leukinreichen kinaseenzyms
|
TWI622406B
(zh)
|
2013-10-23 |
2018-05-01 |
善笙生物科技股份有限公司 |
來自牛樟芝菌絲體的化合物及混合物的用途
|
US9315486B2
(en)
|
2013-10-29 |
2016-04-19 |
Allergan, Inc. |
Therapeutic cyclopentanols, compositions thereof, and methods for use thereof
|
EP3063144B1
(de)
|
2013-11-01 |
2021-09-08 |
Boehringer Ingelheim Animal Health USA Inc. |
Antiparasitäre und pestizide isoxazolinverbindungen
|
WO2015073344A1
(en)
|
2013-11-14 |
2015-05-21 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
KR102331833B1
(ko)
|
2013-12-02 |
2021-11-25 |
케모센트릭스, 인크. |
Ccr6 화합물
|
US9388153B2
(en)
|
2013-12-20 |
2016-07-12 |
Allergan, Inc. |
Secondary amines as therapeutic agents
|
EP3099667B1
(de)
|
2014-01-27 |
2017-11-01 |
Allergan, Inc. |
An mehreren prostaglandinrezeptoren wirkende antagonisten zur behandlung von entzündungen
|
CA2937315A1
(en)
|
2014-02-05 |
2015-08-13 |
Merck Sharp & Dohme Corp. |
Tablet formulation for cgrp-active compounds
|
EP3116475B1
(de)
|
2014-03-13 |
2020-11-04 |
Neuroderm Ltd |
Dopa-decarboxylasehemmerzusammensetzungen
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
WO2015162486A1
(en)
|
2014-04-22 |
2015-10-29 |
Txp Pharma Gmbh |
Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
|
ES2854353T3
(es)
|
2014-04-22 |
2021-09-21 |
Txp Pharma Gmbh |
Análogos péptidicos con sonda(s) aminoacídicas ramificadas
|
WO2015162483A1
(en)
|
2014-04-22 |
2015-10-29 |
Txp Pharma Gmbh |
Alpha- and gamma-msh analogues
|
US9394273B2
(en)
|
2014-05-15 |
2016-07-19 |
Allergan, Inc. |
Therapeutic prostaglandin receptor agonists
|
WO2015179414A1
(en)
|
2014-05-19 |
2015-11-26 |
Merial, Inc. |
Anthelmintic compounds
|
WO2015179815A1
(en)
|
2014-05-22 |
2015-11-26 |
Allergan, Inc. |
Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
|
KR101636758B1
(ko)
*
|
2014-05-30 |
2016-07-06 |
디씨에스이엔지 주식회사 |
회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치
|
US9926262B2
(en)
|
2014-06-06 |
2018-03-27 |
Allergan, Inc. |
EP4 agonists as therapeutic compounds
|
US9908923B2
(en)
|
2014-06-11 |
2018-03-06 |
The Medical College Of Wisconsin, Inc. |
Monomeric CXCL121 peptide and methods of use thereof
|
WO2016009341A1
(en)
|
2014-07-14 |
2016-01-21 |
Radikal Therapeutics Inc. |
Thioredoxin mimetic prodrugs and uses thereof
|
GB201417828D0
(en)
|
2014-10-08 |
2014-11-19 |
Cereno Scient Ab |
New methods and compositions
|
US10954240B2
(en)
|
2014-09-03 |
2021-03-23 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
JP2017528486A
(ja)
|
2014-09-17 |
2017-09-28 |
ヴァーセオン コーポレイション |
セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
|
IL292655B2
(en)
|
2014-10-06 |
2024-03-01 |
Chemocentryx Inc |
CCR9 chemokine receptor inhibitor for use in a method for treating or reducing the development of inflammatory bowel diseases
|
WO2016086261A1
(en)
|
2014-12-02 |
2016-06-09 |
Prana Biotechnology Limited |
4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
|
EP3705469A1
(de)
|
2014-12-09 |
2020-09-09 |
GOLAN, Ezekiel |
Regulatoren für komatrinken
|
EP3258962B1
(de)
|
2015-02-20 |
2022-11-02 |
The Board of Trustees of the Leland Stanford Junior University |
Mischallergenzusammensetzungen verfahren zur verwendung davon
|
KR20170122767A
(ko)
|
2015-02-27 |
2017-11-06 |
베르선 코포레이션 |
세린 프로테아제 저해제로서의 치환된 피라졸 화합물
|
WO2016144862A1
(en)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
JP6995627B2
(ja)
|
2015-05-19 |
2022-02-04 |
イエール ユニバーシティ |
病的石灰化状態を治療するための組成物およびそれを使用する方法
|
CN107835818B
(zh)
|
2015-05-20 |
2022-04-29 |
勃林格殷格翰动物保健美国公司 |
驱虫缩酚酸肽化合物
|
MX2017014818A
(es)
|
2015-05-20 |
2018-02-09 |
Amgen Inc |
Agonistas de triazol del receptor apj.
|
WO2016196429A1
(en)
|
2015-06-03 |
2016-12-08 |
The Medical College Of Wisconsin, Inc. |
An engineered ccl20 locked dimer polypeptide
|
US11571462B2
(en)
|
2015-06-03 |
2023-02-07 |
The Medical College Of Wisconsin, Inc. |
Engineered CCL20 locked dimer polypeptide
|
KR20220062668A
(ko)
|
2015-06-15 |
2022-05-17 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
노화와 연관된 질환을 치료하기 위한 방법 및 조성물
|
JP6871919B2
(ja)
|
2015-06-16 |
2021-05-19 |
ナノファギックス エルエルシー |
薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
|
US9932304B2
(en)
|
2015-06-16 |
2018-04-03 |
University College Dublin, National University Of Ireland, Dublin |
Thromboxane receptor antagonists
|
WO2016205701A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Southern California |
Enteral fast access tract platform system
|
CA2990230A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Southern California |
Compositions and methods for modified nutrient delivery
|
US10294228B2
(en)
|
2015-06-30 |
2019-05-21 |
Neurad Ltd. |
Breathing control modulating compounds, and methods of making and using same
|
US11173197B2
(en)
|
2015-07-07 |
2021-11-16 |
Bluewillow Biologics, Inc. |
Methods and compositions for nanoemulsion vaccine formulations
|
EP3334706B1
(de)
|
2015-08-10 |
2020-09-30 |
Ramot at Tel-Aviv University Ltd. |
Pillararene und verwendungen davon
|
WO2017079260A1
(en)
|
2015-11-02 |
2017-05-11 |
University Of Rochester |
Phosphonate-chloroquine conjugates and methods using same
|
JP2018537526A
(ja)
|
2015-11-02 |
2018-12-20 |
ユニバーシティ オブ ロチェスター |
ボルテゾミブ複合体及びその使用方法
|
WO2017077528A2
(en)
|
2015-11-02 |
2017-05-11 |
Salzman Lovelace Investments, Ltd. |
Methods and pharmaceutical compositions for treatment of lung inflammation
|
TWI734715B
(zh)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
趨化因子受體調節劑
|
TWI724056B
(zh)
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Cxcr2抑制劑
|
JP2018537093A
(ja)
|
2015-11-20 |
2018-12-20 |
イエール ユニバーシティ |
異所性石灰化障害を治療するための組成物およびそれを使用する方法
|
US20170202821A1
(en)
|
2016-01-14 |
2017-07-20 |
Chemocentryx, Inc. |
Method of treating c3 glomerulopathy
|
CA3011639A1
(en)
|
2016-01-20 |
2017-07-27 |
Chemocentryx, Inc. |
2-oxindole compounds
|
EP3413882A4
(de)
|
2016-02-11 |
2019-10-09 |
Mordechai Chevion |
Verfahren und pharmazeutische zusammensetzung zur behandlung von neurodegeneration
|
UY37137A
(es)
|
2016-02-24 |
2017-09-29 |
Merial Inc |
Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
|
WO2017153977A1
(en)
|
2016-03-08 |
2017-09-14 |
Salzman Lovelace Investments, Ltd. |
Solid formulations of resolvins and uses thereof
|
JP7121722B2
(ja)
|
2016-04-04 |
2022-08-18 |
ケモセントリックス,インコーポレイティド |
可溶性C5aRアンタゴニスト
|
WO2017177037A1
(en)
|
2016-04-06 |
2017-10-12 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
WO2017192485A1
(en)
|
2016-05-03 |
2017-11-09 |
Amgen Inc. |
Heterocyclic triazole compounds as agonists of the apj receptor
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
KR102283536B1
(ko)
|
2016-06-03 |
2021-07-30 |
노바사이트, 인코포레이티드 |
폴리머 링커 및 이의 용도
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
JP7185532B2
(ja)
|
2016-06-27 |
2022-12-07 |
ケモセントリックス,インコーポレイティド |
免疫調節化合物
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
WO2018039508A1
(en)
|
2016-08-25 |
2018-03-01 |
Merial, Inc. |
Method for reducing unwanted effects in parasiticidal treatments
|
US10449230B2
(en)
|
2016-10-06 |
2019-10-22 |
The Regents Of The University Of California |
Polymyxin derived cell penetrating scaffolds
|
US10653144B2
(en)
|
2016-10-14 |
2020-05-19 |
Boehringer Ingelheim Animal Health USA Inc. |
Pesticidal and parasiticidal vinyl isoxazoline compounds
|
WO2018085307A1
(en)
|
2016-11-03 |
2018-05-11 |
Wu Laurence I |
Prodrugs of clofarabine
|
CA3040919A1
(en)
|
2016-11-07 |
2018-05-11 |
Arbutus Biopharma Corporation |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
US10736883B2
(en)
|
2016-11-16 |
2020-08-11 |
Amgen Inc. |
Triazole furan compounds as agonists of the APJ receptor
|
EP3541802A1
(de)
|
2016-11-16 |
2019-09-25 |
Amgen Inc. |
Alkylsubstituierte triazolverbindungen als agonisten des apj-rezeptors
|
CN110167921A
(zh)
|
2016-11-16 |
2019-08-23 |
勃林格殷格翰动物保健美国公司 |
驱蠕虫缩肽化合物
|
US10906890B2
(en)
|
2016-11-16 |
2021-02-02 |
Amgen Inc. |
Triazole phenyl compounds as agonists of the APJ receptor
|
US10689367B2
(en)
|
2016-11-16 |
2020-06-23 |
Amgen Inc. |
Triazole pyridyl compounds as agonists of the APJ receptor
|
WO2018097945A1
(en)
|
2016-11-16 |
2018-05-31 |
Amgen Inc. |
Heteroaryl-substituted triazoles as apj receptor agonists
|
MA46827A
(fr)
|
2016-11-16 |
2019-09-25 |
Amgen Inc |
Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
|
RU2022102328A
(ru)
|
2016-11-23 |
2022-04-01 |
Хемоцентрикс, Инк. |
Способ лечения фокально-сегментарного гломерулосклероза
|
WO2018106928A1
(en)
|
2016-12-08 |
2018-06-14 |
Contravir Pharmaceuticals, Inc. |
Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
|
RU2757218C2
(ru)
|
2016-12-14 |
2021-10-12 |
Интервет Интернэшнл Б.В. |
Аминопиразолы в качестве селективных ингибиторов янус-киназы
|
AU2018238138A1
(en)
|
2017-03-21 |
2019-10-17 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
EP3606527A1
(de)
|
2017-04-03 |
2020-02-12 |
Coherus Biosciences, Inc. |
Ppar-gamma-agonist zur behandlung der progressiven supranuklearen blickparese
|
AR111464A1
(es)
|
2017-04-14 |
2019-07-17 |
Contravir Pharmaceuticals Inc |
Terapia combinada para el tratamiento de infecciones virales
|
DE202017002464U1
(de)
|
2017-05-09 |
2017-06-12 |
St. Lotus Biotech Corp. |
Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
|
US11484543B2
(en)
|
2017-05-18 |
2022-11-01 |
The Rockefeller University |
Compositions and methods for diagnosing and treating diseases and disorders associated with mutant KCNJ5
|
PL3641769T3
(pl)
|
2017-06-20 |
2022-09-26 |
Imbria Pharmaceuticals, Inc. |
Pochodna 1-[(2,3,4-trimetoksyfenylo)metylo]piperazyny, jej kompozycje oraz sposoby zwiększania wydajności metabolizmu serca
|
ES2926540T3
(es)
|
2017-08-08 |
2022-10-26 |
Chemocentryx Inc |
Inmunomoduladores macrocíclicos
|
JP2020530850A
(ja)
|
2017-08-14 |
2020-10-29 |
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド |
殺有害生物および殺寄生生物ピラゾール−イソキサゾリン化合物
|
AR112831A1
(es)
|
2017-09-25 |
2019-12-18 |
Chemocentryx Inc |
Terapia de combinación usando un antagonista del receptor 2 de quimiocina (ccr2) y un inhibidor de pd-1 / pd-l1
|
RU2020113612A
(ru)
|
2017-10-11 |
2021-11-12 |
Хемоцентрикс, Инк. |
Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
|
US11149040B2
(en)
|
2017-11-03 |
2021-10-19 |
Amgen Inc. |
Fused triazole agonists of the APJ receptor
|
CN111818929A
(zh)
|
2017-11-27 |
2020-10-23 |
由卫生与公众服务部部长代表的美利坚合众国 |
用于治疗和/或预防牙周疾病的化合物、组合物和方法
|
US10828285B2
(en)
|
2017-12-22 |
2020-11-10 |
Chemocentryx, Inc. |
Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
|
WO2019141957A1
(en)
|
2018-01-19 |
2019-07-25 |
Cado Biotechnology Ivs |
N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
|
WO2019157241A1
(en)
|
2018-02-08 |
2019-08-15 |
Boehringer Ingelheim Animal Health USA Inc. |
Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
|
CA3091088A1
(en)
|
2018-02-13 |
2019-08-22 |
Beetlebung Pharma Ltd. |
Cannabinoid derivatives and conjugates and uses thereof
|
MA51232A
(fr)
|
2018-02-22 |
2020-10-07 |
Chemocentryx Inc |
Indane-amines utiles en tant qu'antagonistes de pd-l1
|
EP3759225A1
(de)
|
2018-03-02 |
2021-01-06 |
Sixfold Bioscience Ltd. |
Zusammensetzungen zur abgabe einer ladung an zellen
|
WO2019191032A1
(en)
|
2018-03-26 |
2019-10-03 |
Clear Creek Bio, Inc. |
Compositions and methods for inhibiting dihydroorotate dehydrogenase
|
WO2019190822A1
(en)
|
2018-03-28 |
2019-10-03 |
Vtv Therapeutics Llc |
Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
WO2019190823A1
(en)
|
2018-03-28 |
2019-10-03 |
Vtv Therapeutics Llc |
Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
|
US20190300526A1
(en)
|
2018-04-02 |
2019-10-03 |
Chemocentryx, Inc. |
PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
|
EP3552605A1
(de)
|
2018-04-11 |
2019-10-16 |
Univerzita Palackého V Olomouchi |
Mcoppb zur verwendung als arzneimittel
|
WO2019213006A1
(en)
|
2018-05-01 |
2019-11-07 |
Amgen Inc. |
Substituted pyrimidinones as agonists of the apj receptor
|
SG11202011534YA
(en)
|
2018-05-29 |
2020-12-30 |
Cersci Therapeutics Inc |
Compounds for pain treatment, compositions comprising same, and methods of using same
|
WO2019236984A1
(en)
|
2018-06-08 |
2019-12-12 |
The Medical College Of Wisconsin, Inc. |
Methods of treating vascular leakage using cxcl12 peptides
|
AU2019301510A1
(en)
|
2018-07-09 |
2021-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Anthelminthic heterocyclic compounds
|
CN112789037A
(zh)
|
2018-09-06 |
2021-05-11 |
创新药物筛选有限公司 |
用于治疗哮喘或帕金森病的方法和药物组合物
|
JP7464591B2
(ja)
|
2018-10-10 |
2024-04-09 |
ブイティーブイ・セラピューティクス・エルエルシー |
[3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物
|
EP3866794A4
(de)
|
2018-10-17 |
2022-07-20 |
Imbria Pharmaceuticals, Inc. |
Verfahren zur behandlung von rheumatischen erkrankungen unter verwendung von trimetazidinbasierten verbindungen
|
WO2020092136A1
(en)
|
2018-10-31 |
2020-05-07 |
Merck Sharp & Dohme Corp. |
N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
CN113260419A
(zh)
|
2018-11-20 |
2021-08-13 |
勃林格殷格翰动物保健美国公司 |
吲唑基氰基乙基氨基化合物、其组合物、其制备方法和其使用方法
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
WO2020159588A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
EP3941587A1
(de)
|
2019-03-19 |
2022-01-26 |
Boehringer Ingelheim Animal Health USA Inc. |
Anthelmintische aza-benzothiophen- und aza-benzofuranverbindungen
|
EP3965792A4
(de)
|
2019-05-09 |
2023-01-18 |
The Feinstein Institutes for Medical Research |
Hmgb1-antagonist
|
WO2020243612A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
US20220259188A1
(en)
|
2019-06-06 |
2022-08-18 |
Merck Sharp & Dohme Corp. |
1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
|
KR20220058530A
(ko)
|
2019-07-08 |
2022-05-09 |
레졸루트 인크 |
혈장 칼리크레인 억제제의 제조 방법
|
US11872217B2
(en)
|
2019-07-10 |
2024-01-16 |
Chemocentryx, Inc. |
Indanes as PD-L1 inhibitors
|
MX2022001596A
(es)
|
2019-08-08 |
2022-03-11 |
Rigel Pharmaceuticals Inc |
Compuestos y metodos para tratar sindrome de liberacion de citocinas.
|
EP4013420B1
(de)
|
2019-08-14 |
2023-11-01 |
Rigel Pharmaceuticals, Inc. |
Verfahren zur blockierung oder linderung des zytokinfreisetzungssyndroms
|
US10792360B1
(en)
|
2019-11-21 |
2020-10-06 |
Chemocentryx, Inc. |
Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
|
WO2021123394A1
(en)
|
2019-12-20 |
2021-06-24 |
University Of Copenhagen |
G protein-coupled receptor modulators and a pharmaceutical composition
|
WO2021195475A1
(en)
|
2020-03-27 |
2021-09-30 |
Aclaris Therapeutics, Inc. |
Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds
|
TW202203916A
(zh)
|
2020-03-31 |
2022-02-01 |
美商卡默森屈有限公司 |
使用ccr9抑制劑及抗il—23阻斷抗體治療發炎性腸道疾病的組成物及方法
|
WO2021216978A1
(en)
|
2020-04-23 |
2021-10-28 |
Aztherapies, Inc. |
Cellular ablation of hla-class i mhc
|
EP3901160A1
(de)
|
2020-04-25 |
2021-10-27 |
Nuvamid SA |
Nicotinamidmononukleotid- und nicotinamidribosidderivate und ihre verwendung zur behandlung von virusinfektionen und respiratorische komplikationen, insbesondere verursacht duch influenzavirus oder coronavirus
|
JP2023522383A
(ja)
|
2020-04-24 |
2023-05-30 |
ヌヴァミド エスアー |
ニコチンアミドモノヌクレオチド及びニコチンアミドリボシド誘導体、並びに特にインフルエンザウィルス又はコロナウィルスによって引き起こされるウィルス感染症及び呼吸器合併症の治療におけるそれらの使用
|
WO2021220053A2
(en)
|
2020-04-27 |
2021-11-04 |
Sixfold Bioscience Ltd. |
Compositions containing nucleic acid nanoparticles with modular functionality
|
AU2021262813A1
(en)
|
2020-04-30 |
2022-11-03 |
Annette M. TOBIA |
Compositions and methods for treating cytokine storms
|
JP2023531378A
(ja)
|
2020-05-28 |
2023-07-24 |
エーゼットセラピーズ, インコーポレイテッド |
神経変性疾患を治療するためのCAR-Treg系療法
|
CA3183100A1
(en)
|
2020-05-29 |
2021-12-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Anthelmintic heterocyclic compounds
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
CN116234539A
(zh)
|
2020-07-07 |
2023-06-06 |
Atxa治疗有限公司 |
血栓素受体拮抗剂调配物
|
EP4182326A1
(de)
|
2020-07-17 |
2023-05-24 |
Université de Bretagne Occidentale |
Neue glycolipide und ihre verwendung als sk3-ionenkanalmodulatoren
|
WO2022029275A1
(en)
|
2020-08-06 |
2022-02-10 |
Nuvamid Sa |
Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
|
US20230321131A1
(en)
|
2020-08-07 |
2023-10-12 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
|
AU2021324066A1
(en)
|
2020-08-12 |
2023-03-30 |
Txp Pharma Ag |
Exendin-4 peptide analogues
|
CA3198225A1
(en)
|
2020-10-13 |
2022-04-21 |
Betavive Ltd. |
Method and compounds for treating diabetes and associated metabolic diseases
|
GB202017251D0
(en)
|
2020-10-30 |
2020-12-16 |
Queens Univ Of Belfast |
Neurodegenerative treatment
|
GB202017255D0
(en)
|
2020-10-30 |
2020-12-16 |
Queens Univ Of Belfast |
Immunomodulatory agent
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
US11730733B2
(en)
|
2020-12-10 |
2023-08-22 |
Imbria Pharmaceuticals, Inc. |
Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
|
US11793807B2
(en)
|
2020-12-10 |
2023-10-24 |
Imbria Pharmaceuticals, Inc. |
Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
|
CA3200596C
(en)
|
2020-12-18 |
2024-02-20 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
|
AU2021409718A1
(en)
|
2020-12-22 |
2023-07-13 |
Allergan Pharmaceuticals International Limited |
Treatment of migraine
|
CN116940350A
(zh)
|
2021-02-08 |
2023-10-24 |
博施健康爱尔兰有限公司 |
预防、治疗或改善溃疡性结肠炎的阿米莫德
|
WO2022184685A1
(en)
|
2021-03-01 |
2022-09-09 |
Nuvamid Sa |
Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19
|
EP4070799A1
(de)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Zusammensetzungen zur verbesserung der sportlichen leistung
|
EP4079310A1
(de)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn und derivate zur verwendung in der behandlung von alpha-synucleinopathien
|
EP4079311A1
(de)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn und derivate zur verwendung davon bei der behandlung von depression und/oder angst bei patienten mit einer form von parkinsonismus
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|
EP4346763A1
(de)
|
2021-05-31 |
2024-04-10 |
Cannabotech Ltd. |
Zusammensetzungen mit einem cannabinoid und verwendungen davon
|
EP4355335A1
(de)
|
2021-06-17 |
2024-04-24 |
Nuvamid SA |
Nicotinamid-mononukleotid-derivate und ihre verwendung zur behandlung von herzinsuffizienz mit konservierter ejektionsfraktion
|
WO2022263676A1
(en)
|
2021-06-18 |
2022-12-22 |
University Of Copenhagen |
Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
|
CA3227520A1
(en)
|
2021-08-02 |
2023-02-09 |
Laurent GARCON |
Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
|
WO2023062545A1
(en)
|
2021-10-12 |
2023-04-20 |
Betavive Ltd. |
Peptides and fragments for treating diabetes and associated metabolic diseases
|
US20240116945A1
(en)
|
2022-09-02 |
2024-04-11 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|